The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jeremy Grolick - GunnAllen Financial - Analyst
: Hi, I'm very happy with the progress that you guys have made as of today. There's only one thing on the conference calls that we love to hear and
I've been a shareholder from the inception with healthcare acquisition.
I would like to ask a question with regards to PR, public relations, with regards to getting the word out to the street -- volume has been a little light.
I know a lot of shares are institutionally held as well as insider -- as well as being insider held. Is there anything that you guys, going forward over
the near term, are out there on a daily basis telling your story?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Jeremy Grolick - GunnAllen Financial - Analyst
: All right. I'm also -- like I said, I'm very pleased with the -- to date, what's going on and I'm in it for the long haul, but do you guys have an idea who
else put in an RFP?
And I was doing a little research on this and it says that the government is looking to initiate procurement -- I guess there's no guarantees on the
date -- at the end of September of '08. Has that changed now, from your comments as of year end of this year?
Question: Jeremy Grolick - GunnAllen Financial - Analyst
: Okay. So the --
Question: Jeremy Grolick - GunnAllen Financial - Analyst
: Okay. Very good.
Question: Jeremy Grolick - GunnAllen Financial - Analyst
: Thank you.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Thank you. David, hi. Congratulations on all of the progress.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Just following up on that gentleman's question about the RFP. You mentioned the delays due to additional people looking to be part of the process.
What's your expectation on how many winners there are going to be? It's not a winner take all, I don't suspect.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay, and in terms of pricing per dose. Should we just do the math? You said earlier $350 million to $600 million opportunity. Divide that by 50
million doses?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: And that's based on 50 million doses? That's the total contract to the winners?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: So the $350 million to $600 million would be one of the two winners.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Super. And in terms of the cash balances, I understand the restriction for the letters of credit with Silicon and the Avecia deal. Do you have any
auction rate preferreds at this time?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Auction rate securities for your cash.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay. And then in terms of the NIAID contract for the next gen on the rPA anthrax, any range you can give us on the potential size of that contract?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: And how many competitors have next gen rPA?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: And again, is that -- would there be multiple winners there as well?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay. And can you give us any color on the pipeline for [M&A]? I know you just closed on Avecia but anything else brewing?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay, and last question. What was the name of the new IR firm?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay. Do you also have an IR firm for the street or is this PR firm taking both over?
Question: Gary Siperstein - Eliot Rose Asset Management - Analyst
: Okay, thank you very much.
| 
